A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Latest Information Update: 19 Jan 2026
At a glance
- Drugs 707 3SBio (Primary) ; Antineoplastics; Atezolizumab
- Indications Small cell lung cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 12 Jan 2026 Status changed from not yet recruiting to recruiting.
- 17 Nov 2025 New trial record